Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at Guggenheim

Maze Therapeutics (NASDAQ:MAZE) had its target price boosted by analysts at Guggenheim from $46.00 to $58.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price target would suggest a potential upside of 31.28% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. Raymond James Financial initiated coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They set an “outperform” rating and a $48.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Finally, Wedbush increased their price target on Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Maze Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $48.57.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $44.18 on Wednesday. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $49.25. The stock has a 50 day simple moving average of $43.70 and a two-hundred day simple moving average of $33.95. The company has a market cap of $2.13 billion, a P/E ratio of -2.11 and a beta of 4.47.

Insider Buying and Selling

In related news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the sale, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $464,967.81. This represents a 41.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $596,908.60. This represents a 27.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 200,000 shares of company stock worth $8,254,792.

Institutional Investors Weigh In On Maze Therapeutics

A number of institutional investors have recently added to or reduced their stakes in MAZE. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares during the last quarter. CWM LLC bought a new stake in Maze Therapeutics during the second quarter worth $28,000. GF Fund Management CO. LTD. bought a new stake in Maze Therapeutics during the fourth quarter worth $39,000. Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Maze Therapeutics in the 4th quarter valued at $43,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.